Glypican-3 (GPC3)-Positive Squamous Non-small Cell Lung Cancer

Explore clinical trials studying Glypican-3 (GPC3)-Positive Squamous Non-small Cell Lung Cancer. Study availability and eligibility vary by location and protocol.

1 public trial 1 recruiting study

Refine in advanced search Browse all conditions

Glypican-3 (GPC3)-Positive Squamous Non-small Cell Lung Cancer trial results

Recruiting

A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors

NCT06427941

Conditions: Adenocarcinoma, Alpha-fetoprotein (AFP)-Producing Gastric Cancer, Carcinoma, +14 more
Locations: City of Hope Phoenix Cancer Center Goodyear, Arizona, United States

City of Hope National Medical Center Duarte, California, United States

City of Hope Chicago Cancer Center Zion, Illinois, United States

Memorial Sloan Kettering Cancer Center Mskcc New York, United States

View all 47 locations

View Trial Details

Glypican-3 (GPC3)-Positive Squamous Non-small Cell Lung Cancer

Glypican-3 (GPC3)-Positive Squamous Non-small Cell Lung Cancer trial results

A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors

Related conditions